Document is current
Any future updates will be listed below
-
Authors
Weerasekera, Akila https://orcid.org/0000-0003-0446-7604
Coelho, David Richer Araujo https://orcid.org/0000-0003-4217-2399
Ratai, Eva-Maria
Collins, Katherine Anne
Puerto, Aura Maria Hurtado
De Taboada, Luis
Gersten, Maia Beth
Clancy, Julie A
Hoptman, Matthew J
Irvin, Molly Kennedy
Sparpana, Allison Mary
Sullivan, Elizabeth F
Song, Xiaotong
Adib, Arwa
Cassano, Paolo https://orcid.org/0000-0003-0225-199X
Iosifescu, Dan Vlad https://orcid.org/0000-0002-2512-2835
-
Funding
Funding for this research was provided by:
National Institutes of Health (R61 MH122647)
National Institutes of Health (R33 MH122647)
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 23 September 2024
First Online: 7 October 2024
Declarations
:
: ER is a member of the scientific review board of BrainSpec. Matthew J. Hoptman reports financial support was provided by American Foundation for Suicide Prevention. Matthew J. Hoptman reports a relationship with Kessler Research Foundation that includes consulting or advisory and serves on the Editorial board of Brain Sciences and is an Associate Editor for Frontiers of Psychiatry - Schizophrenia Section. PC consulted for Janssen Research and Development and for Niraxx Inc; was funded by PhotoThera Inc., LiteCure LLC and Cerebral Sciences Inc to conduct studies on transcranial photobiomodulation; is a shareholder of Niraxx Inc; and has filed several patents related to the use of near infrared light in psychiatry. In the last 5 years, DVI has received consulting honoraria from Alkermes, Allergan, Axsome, Biogen, Centers for Psychiatric Excellence, Jazz, Lundbeck, Otsuka, Precision Neuroscience, Sage, and Sunovion and has received research support (through his academic institutions) from Alkermes, AstraZeneca, Brainsway, Litecure, Neosync, Otsuka, Roche, and Shire. The other authors have nothing to disclose.
